reports
Cidara Therapeutics to Report Second Quarter 2025 Financial Results an...
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss t...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
HELE HELEN OF TROY LIMITED
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
CIVB CIVISTA BANCSHARES
NXRT NEXPOINT RESIDENTIAL TRUST INC.
DYN DYNEGY INC.
GIII G-III APPAREL GROUP LTD.
PETS PETMED EXPRESS INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRSP CRISPR THERAPEUTICS AG
CRVL CORVEL CORP.
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
COGT COGINT
BWB INC.
DOMO BRIDGEWATER BANCSHARES
FGBI DOMO INCORPORATED
PVH FIRST GUARANTY BANCSHARES
GRX PHILLIPS-VAN HEUSEN CORPORATION
INLX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
FRHC INTELLINETICS
CMTV INC.
RZLT FREEDOM HOLDING CORP
KYMR COMMUNITY BANCORP INC. VT
BTBT REZOLUTE
TERN INC.
CTO KYMERA THERAPEUTICS
VERA BIT DIGITAL (N SHARES)
IMRX TERNS PHARMACEUTICALS
BRCC CONSOLIDATED-TOMOKA LAND CO
BPRN VERA THERAPEUTICS INC
PMNT IMMUNEERING CORP
NYC BRC INC
ACTU BANK OF PRINCETON
MBRX PERFECT MOMENT LTD.
LION NEW YORK CITY REIT
THAR INC.
FGEN ACTUATE THERAPEUTICS INC.
CCIF MOLECULIN BIOTECH INC.
BMNR LIONSGATE STUDIOS CORP
NEGG THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
BITMINE IMMERSION TECHNOLOGIES INC.
NEWEGG COMMERCE INC.
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRVL CORVEL CORP.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
RSSS RESEARCH SOLUTIONS
BWB BRIDGEWATER BANCSHARES
DOMO DOMO INCORPORATED
FGBI FIRST GUARANTY BANCSHARES
PVH PHILLIPS-VAN HEUSEN CORPORATION
AMPY AMPLIFY ENERGY
INLX INTELLINETICS
FRHC INC.
CMTV FREEDOM HOLDING CORP
RZLT COMMUNITY BANCORP INC. VT
KYMR REZOLUTE
WSC INC.
BTBT KYMERA THERAPEUTICS
TERN WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB BIT DIGITAL (N SHARES)
CTO TERNS PHARMACEUTICALS
VERA NUVATION BIO INC (A)
IMRX CONSOLIDATED-TOMOKA LAND CO
XLO VERA THERAPEUTICS INC
SSBK IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU PERFECT MOMENT LTD.
SUNS NEW YORK CITY REIT
MBRX INC.
LION ACTUATE THERAPEUTICS INC.
HYMC SUNRISE REALTY TRUST
THAR MOLECULIN BIOTECH INC.
FGEN LIONSGATE STUDIOS CORP
CCIF HYCROFT MINING HOLDING CORPORATION
BTCS THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
TOUCHIT TECHNOLOGIES
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
PSEC PROSPECT CAPITAL CORPORATION
NG. NOVAGOLD RESOURCES INC.
WELL WELLTOWER INC.
CDXS CODEXIS
CDTX CIDARA THERAPEUTICS
AMPH AMPHASTAR PHARMACEUTICALS INC
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
MLP MAUI LAND & PINEAPPLE CO. INC.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
STKL SUNOPTA
RSSS INC.
BWB RESEARCH SOLUTIONS
DOMO BRIDGEWATER BANCSHARES
SONO DOMO INCORPORATED
A2JHXF SONOS
FGBI CEVA LOGISTICS AG
PVH FIRST GUARANTY BANCSHARES
AMPY PHILLIPS-VAN HEUSEN CORPORATION
INLX AMPLIFY ENERGY
FRHC INTELLINETICS
RZLT INC.
KYMR FREEDOM HOLDING CORP
WSC REZOLUTE
BTBT INC.
TERN KYMERA THERAPEUTICS
NUVB WILLSCOT MOBILE MINI HOLDINGS CORP
CTO BIT DIGITAL (N SHARES)
VERA TERNS PHARMACEUTICALS
IMRX NUVATION BIO INC (A)
XLO CONSOLIDATED-TOMOKA LAND CO
SSBK VERA THERAPEUTICS INC
NCDL IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU NUVEEN CHURCHILL DIRECT LENDING CORP
SUNS PERFECT MOMENT LTD.
MBRX NEW YORK CITY REIT
HYMC INC.
THAR ACTUATE THERAPEUTICS INC.
FGEN SUNRISE REALTY TRUST
CCIF MOLECULIN BIOTECH INC.
HYCROFT MINING HOLDING CORPORATION
THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for an aggregate of 12,100 shares of its common stock to two new employees, pursuant to the Cidara Therapeutics, ...
- Jonathan Moreland
CDTX CIDARA THERAPEUTICS
GRF EAGLE CAPITAL GROWTH FUND INC
PVH PHILLIPS-VAN HEUSEN CORPORATION
TERN TERNS PHARMACEUTICALS
IMRX IMMUNEERING CORP
SONM SONIM TECHNOLOGIES INC
ACTU ACTUATE THERAPEUTICS INC.
DSM DREYFUS STRATEGIC MUNICIPAL BOND FUND
LION INC.
CCIF LIONSGATE STUDIOS CORP
CARLYLE CREDIT INCOME FUND
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russe...
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to the Russell 2000® and Russell 3000® Indexes. The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investable U.S. equity market. The Russell 2000 Index is a subset of the Russell 3000, m...
Cidara Announces Closing of Upsized Public Offering and Full Exercise ...
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per sh...
Cidara Announces Pricing of Upsized Public Offering of Common Stock
Cidara Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price to the public of $44.00 per share. All of the shares are to be sold by Cidara. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering ex...
Cidara Announces Proposed Public Offering of Common Stock
Cidara Announces Proposed Public Offering of Common Stock SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to...
Cidara Therapeutics Announces Positive Topline Results from its Phase ...
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo CD388 was well-tolerated with no safety signals observed End of Phase 2 meeting request has been submitted to the U.S. Food and Drug Administration (FDA) Cidara will host a conference...
Cidara Therapeutics Inc: 1 director
A director at Cidara Therapeutics Inc maiden bought 3,320 shares at 22.258USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Pote...
Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, The event will feature key opinion leaders (KOLs) Fred Hayde...
Cidara Therapeutics to Participate in Two Upcoming Investor Conference...
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 10:00 AM ET Event: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:40 AM ET The live webcast for the presentations can be ac...
Cidara Therapeutics Provides Corporate Update and Reports First Quarte...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a...
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief ...
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, M.D., J.D. has been promoted to chief medical officer (CMO), and Corrina Pavetto has been promoted to senior vice president, clinical development, effective May 1, 2025. “These promotions come at a pivotal time as we ...
Cidara Therapeutics to Participate in The Citizens Life Sciences Confe...
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference. Details are as follows: Event: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025Time: 11:00 AM ET Format: Presentation Webcast: A replay of the presentation will be available in the Investors sec...
Cidara Therapeutics to Report First Quarter 2025 Financial Results and...
Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025 SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discus...
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule...
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted Timothy Alefantis, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 27,000 shares of its common stock, pursuant to the Cidara...
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual ...
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that company management will participate in the 24th Annual Needham Virtual Healthcare Conference. Details are as follows: Event: 24th Annual Needham Virtual Healthcare ConferenceDate: Wednesday, April 9, 2025Time: 11:00 AM ET Format: Presentation Webcast: A replay of the pre...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.